Newborn screening for SMA in Southern Belgium.


Journal

Neuromuscular disorders : NMD
ISSN: 1873-2364
Titre abrégé: Neuromuscul Disord
Pays: England
ID NLM: 9111470

Informations de publication

Date de publication:
05 2019
Historique:
received: 24 05 2018
revised: 07 02 2019
accepted: 11 02 2019
pubmed: 30 4 2019
medline: 13 5 2020
entrez: 30 4 2019
Statut: ppublish

Résumé

Approval was recently granted for a new treatment for spinal muscular atrophy (SMA). Given that the treatment is effective when administered early and the societal burden of SMA-related disability, the implementation of a newborn screening program is warranted. We describe the stepwise process that led us to launch a newborn screening program for SMA in Southern Belgium. Different political, ethical, and clinical partners were informed about this project and were involved in its governance, as were genetic and screening labs. We developed and validated a newborn screening method to specifically recognize homozygous deletions of exon 7 in the SMN1 gene. Subsequently, a 3-year pilot study has been recently initiated in one Belgian neonatal screening laboratory to cover 17.000 neonates per year. Coverage extension to all of Southern Belgium to screen 55.000 babies each year is underway.

Identifiants

pubmed: 31030938
pii: S0960-8966(18)30482-6
doi: 10.1016/j.nmd.2019.02.003
pii:
doi:

Substances chimiques

Oligonucleotides 0
SMN1 protein, human 0
Survival of Motor Neuron 1 Protein 0
nusinersen 5Z9SP3X666

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

343-349

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

François Boemer (F)

Biochemical Genetics Lab, Department of Human Genetics, CHU of Liege, University of Liege, Liege 4000, Belgium. Electronic address: f.boemer@chuliege.be.

Jean-Hubert Caberg (JH)

Molecular Genetics Lab, Department of Human Genetics, CHU of Liege, University of Liege, Liege, Belgium.

Vinciane Dideberg (V)

Molecular Genetics Lab, Department of Human Genetics, CHU of Liege, University of Liege, Liege, Belgium.

Domien Dardenne (D)

Molecular Genetics Lab, Department of Human Genetics, CHU of Liege, University of Liege, Liege, Belgium.

Vincent Bours (V)

Department of Human Genetics, CHU of Liege, University of Liege, Liege, Belgium.

Mickaël Hiligsmann (M)

Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands.

Tamara Dangouloff (T)

I-Motion, Platform for Pediatric Clinical Trials, Arnold Trousseau Hospital, Paris, France; Neuromuscular Center, CHR Citadelle, University of Liege, Liege, Belgium.

Laurent Servais (L)

I-Motion, Platform for Pediatric Clinical Trials, Arnold Trousseau Hospital, Paris, France; Neuromuscular Center, CHR Citadelle, University of Liege, Liege, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH